Study on Inhaled Levofloxacin for Treating Community-Acquired Pneumonia in Patients Without Systemic Antibiotics

2 1 1

What is this study about?

This clinical trial is focused on studying the treatment of community-acquired pneumonia, a type of lung infection that people can get outside of a hospital setting. The study is comparing two different treatments to see which is more effective. One treatment involves using an inhaled medication called levofloxacin, which is a type of antibiotic that helps fight bacteria in the lungs. The other treatment uses a combination of two antibiotics, piperacillin and tazobactam, which are given through an intravenous infusion, meaning they are delivered directly into the bloodstream through a vein.

The purpose of the study is to determine if the inhaled levofloxacin treatment is as effective as the intravenous piperacillin/tazobactam treatment in helping patients recover from pneumonia. Participants in the study will receive one of these treatments for 4 to 5 days. The study will monitor how many days patients are alive and out of the hospital within 14 days after starting treatment. This will help researchers understand which treatment allows patients to recover more quickly and safely.

Throughout the study, researchers will also look at other factors, such as any side effects from the antibiotics, changes in the diversity of bacteria in the gut, and overall health outcomes at 30 days. This information will help provide a clearer picture of the benefits and risks of each treatment option for community-acquired pneumonia.

1 hospital admission

Upon joining the study, admission to the hospital occurs within 24 hours.

A new chest infiltrate, visible on a radiological exam, confirms pneumonia, accompanied by symptoms such as fever, cough, sputum, difficulty breathing, or chest pain.

2 initial treatment decision

The attending physician determines the necessity of treatment with intravenous piperacillin/tazobactam.

This decision is based on specific criteria, including a C-reactive protein level greater than 50 or a central body temperature exceeding 38.0°C.

3 treatment with inhaled levofloxacin

The treatment involves inhaling levofloxacin at a dose of 240 mg, administered twice daily.

This treatment continues for a duration of 4 to 5 days, without the use of systemic antibiotics.

4 monitoring and evaluation

The primary goal is to assess the number of days alive and out of the hospital within 14 days.

Secondary evaluations include the number of days alive and out of the hospital at 30 days, and without antibiotics, as well as the occurrence of any antibiotic-related side effects.

5 additional assessments

Further assessments involve changes in gut microbiome diversity and composition from stool and oral samples on day 5 and day 60.

Other measures include all-cause mortality at 30 days, and the proportion of patients readmitted, admitted to ICU, or deceased at 30 days.

6 patient-reported outcomes

Patient-reported outcomes are measured through changes in visual analogue scales for symptoms such as difficulty breathing, cough, and fatigue from day 1 to day 5.

Who Can Join the Study?

Must be admitted to the hospital within the last 24 hours.
Must have a new chest problem seen on an X-ray that looks like pneumonia, along with symptoms like fever, cough, producing mucus, difficulty breathing, and/or chest pain.
The doctor treating the patient has decided that the patient should receive a specific antibiotic treatment called IV piperacillin/tazobactam.
Must have a C-reactive protein level greater than 50, or a body temperature higher than 38.0°C. C-reactive protein is a substance in the blood that increases when there is inflammation or infection.
Must be 18 years of age or older.
Must be able to understand the study and agree to participate by giving informed consent.

Who Cannot Join the Study?

Patients who are currently taking other antibiotics that are not part of the study.
Patients with a history of allergic reactions to the study medications.
Patients with severe liver or kidney problems.
Patients who are pregnant or breastfeeding.
Patients with other serious health conditions that might interfere with the study.
Patients who have participated in another clinical trial recently.
Patients who are unable to follow the study procedures or take the study medication as directed.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Bispebjerg Hospital	Copenhagen	Denmark

Other Sites

Site Name	City	Country
Amager Hospital	Copenhagen	Denmark
Hvqrbxbl Hkenwufd	Hvidovre	Denmark
Hzwraq Hsfrhriy	Herlev	Denmark

Trial status

Country	Status	Recruitment Start
Denmark	Not yet recruiting	01.01.2025

Trial locations

Investigated drugs:

Levofloxacin is an antibiotic used to treat infections. In this trial, it is given through inhalation to help treat community-acquired pneumonia. The goal is to see if using inhaled levofloxacin alone, without other antibiotics, is as effective as other treatments in helping patients recover and stay out of the hospital.

Piperacillin/Tazobactam is a combination of two antibiotics used to treat a variety of infections. In this trial, it is given intravenously, meaning it is administered directly into the bloodstream. The trial aims to compare the effectiveness of this treatment with inhaled levofloxacin in treating community-acquired pneumonia.

Community-acquired pneumonia – This is an infection of the lungs that occurs in individuals who have not recently been hospitalized. It is typically caused by bacteria, viruses, or fungi that are inhaled into the lungs. The disease often begins with symptoms such as cough, fever, and difficulty breathing. As it progresses, patients may experience chest pain, fatigue, and a worsening cough that produces phlegm. In severe cases, it can lead to complications like fluid accumulation in the lungs or difficulty in oxygen exchange. The progression and severity can vary based on the individual’s age, overall health, and the specific pathogen causing the infection.

Trial ID:

2024-511420-13-00

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Inhaled Levofloxacin for Treating Community-Acquired Pneumonia in Patients Without Systemic Antibiotics

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?